公开(公告)号：US20160347858A1

公开(公告)日：2016-12-01

申请号：US15098869

申请日：2016-04-14

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoshimasa Sakamoto ,  Yusuke Adachi ,  Junji Matsui ,  Yu Kato ,  Yoichi Ozawa ,  Takanori Abe ,  Ken Ito ,  Yuya Nakazawa ,  Sho Tachino ,  Katsuhisa Suzuki ,  Kishan Agarwala ,  Kana Hoshino

IPC: C07K16/32 ,  A61K31/337 ,  A61K31/47 ,  A61K39/395 ,  A61K33/24

CPC classification number: C07K16/32 ,  A61K31/337 ,  A61K31/47 ,  A61K33/24 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/705 ,  C07K14/71 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/3023 ,  C07K16/303 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/21 ,  C07K2319/42 ,  C12N9/14 ,  C12Y301/03001 ,  A61K2300/00

Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.

Abstract translation: 本发明提供了可能对人Notch4具有中和活性的抗人Notch4抗体或Notch4结合片段，以及包含与活性成分相同的药物组合物。 本发明人获得了对人Notch4具有高中和活性和结合亲和力的小鼠抗人Notch4抗体，并确定了所述小鼠抗人Notch4抗体的互补决定区（CDR）序列。 这使得能够产生包含重链和轻链的可变区以及所述小鼠抗人Notch4抗体的CDR序列的人源化抗体。

公开(公告)号：US20210261566A1

公开(公告)日：2021-08-26

申请号：US17167480

申请日：2021-02-04

Applicant: President and Fellows of Harvard College ,  Eisai R&D Management Co., LTD.

Inventor： Yoshito Kishi ,  Kazunobu Kira ,  Ken Ito

IPC: C07D493/22 ,  A61K39/395 ,  A61K31/357 ,  C07K16/28 ,  A61P35/00

Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.

公开(公告)号：US20200325152A1

公开(公告)日：2020-10-15

申请号：US16764245

申请日：2018-11-15

Applicant: President and Fellows of Harvard College ,  Eisai R&D Management Co., LTD.

Inventor： Yoshito Kishi ,  Kazunobu Kira ,  Ken Ito

IPC: C07D493/22 ,  A61P35/04

Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.

公开(公告)号：US20200148698A1

公开(公告)日：2020-05-14

申请号：US16500924

申请日：2018-04-03

Applicant: President and Fellows of Harvard College ,  Eisai R&D Management Co., LTD.

Inventor： Yoshito Kishi ,  Kazunobu Kira ,  Ken Ito

IPC: C07D493/22 ,  A61K31/357 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.

公开(公告)号：US20170096493A1

公开(公告)日：2017-04-06

申请号：US15382821

申请日：2016-12-19

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoshimasa Sakamoto ,  Yusuke Adachi ,  Junji Matsui ,  Yu Kato ,  Yoichi Ozawa ,  Takanori Abe ,  Ken Ito ,  Yuya Nakazawa ,  Sho Tachino ,  Katsuhisa Suzuki ,  Kishan Agarwala ,  Kana Hoshino ,  Masahiko Katayama

IPC: C07K16/32 ,  A61K31/337 ,  A61K31/47 ,  A61K39/395 ,  A61K33/24

CPC classification number: C07K16/32 ,  A61K31/337 ,  A61K31/47 ,  A61K33/24 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/705 ,  C07K14/71 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/3023 ,  C07K16/303 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/21 ,  C07K2319/42 ,  C12N9/14 ,  C12Y301/03001 ,  A61K2300/00

Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.